Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial
暂无分享,去创建一个
T. Yamanaka | M. Okada | A. Kubo | Y. Nakanishi | K. Azuma | I. Okamoto | H. Murakami | T. Seto | K. Nakagawa | N. Nogami | S. Sugawara | K. Yonesaka | M. Takeda | T. Hirashima | H. Hayashi | H. Saito | T. Sawa | H. Daga | Y. Urata | E. Miyahara